After identifying that RIPK1 and RIPK3 inhibition can reduce atherosclerotic lesion size and necrotic core and that phosphorylated MLKL is present in human atherosclerotic plaque, Rasheed et al. pursued an investigation into the role of MLKL in atherosclerosis [26]. Here, RIPK3 is linked to atherosclerosis.